Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation.
作者信息
Asawapanumas Thiti, Chanswangphuwana Chantiya, Watanaboonyongcharoen Phandee, Rojnuckarin Ponlapat, Bunworasate Udomsak
机构信息
Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, Thailand.
出版信息
Leuk Res Rep. 2022 Apr 13;17:100314. doi: 10.1016/j.lrr.2022.100314. eCollection 2022.
Abstract
摘要
相似文献
1
Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation.
Leuk Res Rep. 2022 Apr 13;17:100314. doi: 10.1016/j.lrr.2022.100314. eCollection 2022.
2
Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment.
Acta Haematol. 2021;144(6):683-687. doi: 10.1159/000515257. Epub 2021 Apr 22.
3
Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantation.
Transfusion. 2021 Apr;61(4):1041-1046. doi: 10.1111/trf.16281. Epub 2021 Feb 2.
4
Case report: Successful treatment with daratumumab for pure red cell aplasia in a patient with mixed lymphoid chimerism after ABO-mismatched stem cell transplant for sickle cell disease.
Front Immunol. 2023 Jun 23;14:1212007. doi: 10.3389/fimmu.2023.1212007. eCollection 2023.
5
Oral High Dose Dexamethasone for Pure Red Cell Aplasia Following ABO-Mismatched Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report.
Indian J Hematol Blood Transfus. 2015 Jun;31(2):317-8. doi: 10.1007/s12288-013-0276-x. Epub 2013 Jun 9.
6
Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab.
Eur J Haematol. 2020 Feb;104(2):145-147. doi: 10.1111/ejh.13343. Epub 2019 Nov 20.
7
Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant.
J Clin Apher. 2018 Feb;33(1):108-112. doi: 10.1002/jca.21553. Epub 2017 May 24.
8
Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation.
Bone Marrow Transplant. 2022 Feb;57(2):282-285. doi: 10.1038/s41409-021-01507-3. Epub 2021 Oct 28.
9
Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia.
Blood Cells Mol Dis. 2021 May;88:102464. doi: 10.1016/j.bcmd.2020.102464. Epub 2020 Jul 2.
10
Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation.
Br J Haematol. 2013 Mar;160(6):798-805. doi: 10.1111/bjh.12210. Epub 2013 Jan 18.
引用本文的文献
1
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party.
Blood Cancer J. 2025 Jun 4;15(1):106. doi: 10.1038/s41408-025-01315-8.
2
Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature.
World J Clin Cases. 2024 Aug 26;12(24):5604-5612. doi: 10.12998/wjcc.v12.i24.5604.
3
Refractory Pure Red Blood Cell Aplasia Secondary to Major ABO-Incompatible Allogeneic Stem Cell Transplantation Successfully Treated With Daratumumab.
J Hematol. 2023 Dec;12(6):277-282. doi: 10.14740/jh1195. Epub 2023 Dec 9.
4
Case report: Successful treatment with daratumumab for pure red cell aplasia in a patient with mixed lymphoid chimerism after ABO-mismatched stem cell transplant for sickle cell disease.
Front Immunol. 2023 Jun 23;14:1212007. doi: 10.3389/fimmu.2023.1212007. eCollection 2023.
本文引用的文献
1
Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages.
Haemophilia. 2021 Jan;27(1):e155-e159. doi: 10.1111/hae.14118. Epub 2020 Aug 25.
2
Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab.
Eur J Haematol. 2020 Feb;104(2):145-147. doi: 10.1111/ejh.13343. Epub 2019 Nov 20.
3
Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation.
Bone Marrow Transplant. 2020 Jun;55(6):1191-1193. doi: 10.1038/s41409-019-0664-4. Epub 2019 Sep 3.
4
Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.
Am J Hematol. 2019 Aug;94(8):E216-E219. doi: 10.1002/ajh.25515. Epub 2019 Jun 7.
5
Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
Ann Hematol. 2019 May;98(5):1135-1147. doi: 10.1007/s00277-019-03624-y. Epub 2019 Feb 13.
6
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.
Front Immunol. 2018 Nov 15;9:2616. doi: 10.3389/fimmu.2018.02616. eCollection 2018.
7
Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.
N Engl J Med. 2018 Nov 8;379(19):1846-1850. doi: 10.1056/NEJMoa1807438.
8
Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2018 Aug;24(8):1765-1770. doi: 10.1016/j.bbmt.2018.04.022. Epub 2018 Apr 21.
9
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia.
Biol Blood Marrow Transplant. 2016 May;22(5):961-5. doi: 10.1016/j.bbmt.2016.02.008. Epub 2016 Feb 26.
10
Resolving the daratumumab interference with blood compatibility testing.
Transfusion. 2015 Jun;55(6 Pt 2):1545-54. doi: 10.1111/trf.13069. Epub 2015 Mar 12.
Zotero 插件